CN Patent

CN116829151A — 氮杂喹唑啉泛KRas抑制剂

Assigned to Mirati Therapeutics Inc · Expires 2023-09-29 · 3y expired

What this patent protects

本发明涉及抑制KRas G12A、KRas G12C、KRas G12D、KRas G12R、KRas G12S、KRas G12V、KRas G13D和KRas Q61H中的至少一者的化合物、包含所述化合物的药物组合物及其使用方法。

USPTO Abstract

本发明涉及抑制KRas G12A、KRas G12C、KRas G12D、KRas G12R、KRas G12S、KRas G12V、KRas G13D和KRas Q61H中的至少一者的化合物、包含所述化合物的药物组合物及其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116829151A
Jurisdiction
CN
Classification
—
Expires
2023-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.